Seer Inc
Seer Inc is a biotechnology company focused on the development of next-generation sequencing (NGS) platforms for genomic research and clinical applications.
Business. Seer Inc (SEER.O) is a technology equipment company operating within the office equipment industry. The firm generates revenue primarily through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Seer Inc (SEER.O) is a technology equipment company operating within the office equipment industry. The firm generates revenue primarily through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Seer Inc operates with a highly liquid capital structure, as evidenced by its current ratio of 12.84, indicating strong short-term liquidity. The company holds $47.29 million in cash and equivalents, with no long-term debt, and a debt-to-equity ratio of 0.0, suggesting a conservative leverage profile. However, the company's free cash flow is negative at -$69.29 million, reflecting significant cash outflows from operations and capital expenditures.
Profitability metrics show a challenging operating environment for Seer Inc. The company reported a net loss of $73.60 million and an operating loss of $77.99 million, resulting in a return on equity of -28.38% and a return on assets of -24.86%. These figures are well below the industry median for biotechnology firms, which typically report positive returns on equity and assets, indicating that Seer Inc is underperforming in terms of capital efficiency and operational profitability.
Geographically and segment-wise, Seer Inc's revenue is concentrated in a single business line focused on NGS platforms, with no disclosed geographic breakdown in the latest financials. This lack of diversification increases exposure to market-specific risks, particularly in the biotechnology and genomic research sectors, which are subject to regulatory and technological shifts.
Looking ahead, Seer Inc is expected to continue experiencing revenue growth, though the exact magnitude is not quantified in the available data. The company's operating cash flow remains negative, and with a mean EPS estimate of -$1.08, analysts project continued losses in the near term. The company's ability to scale its NGS platform and achieve commercial traction will be critical to improving its financial performance.
Risk factors for Seer Inc include its high burn rate and reliance on continued capital infusions to fund operations. The company has no immediate filing-based liquidity or dilution flags, and its dilution risk is currently assessed as low. However, the negative free cash flow and operating losses suggest a potential need for future equity or debt financing, which could dilute existing shareholders.
Recent events include the continued development of its NGS platform, with no major regulatory or legal issues disclosed in the latest filings. The company's focus on innovation in genomic research positions it to benefit from long-term industry growth, but near-term financial performance remains a concern.
- Seer Inc has a highly liquid balance sheet with $47.29 million in cash and no long-term debt.
- The company is currently unprofitable, with a net loss of $73.60 million and negative returns on equity and assets.
- Revenue is concentrated in a single business line, increasing exposure to sector-specific risks.
- Analysts project continued losses in the near term, with a mean EPS estimate of -$1.08.
- The company's liquidity and dilution risk are currently low, but its negative free cash flow suggests a potential need for future capital raises.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,08 |
| Revenue | —no estimate | —no estimate | 16,6M USD |
| Operating income | —no estimate | —no estimate | -62,9M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Commercial Officer · Employee Stock Option (right to buy) → Class A Common StockAcquired 225 000 @ $1,87grant · 2026-05-08
- PRESIDENT & CFO · Employee Stock Option (right to buy) → Class A Common StockAcquired 119 000 @ $1,79grant · 2026-02-03
- Director, CEO AND CHAIR · Employee Stock Option (right to buy) → Class A Common StockAcquired 512 000 @ $1,79grant · 2026-02-03
- Director · Class B Common Stock → Class A Common StockDisposed 4 088conversion · 2025-12-09
- Director, CEO AND CHAIR · Class B Common Stock → Class A Common StockDisposed 1 438 057conversion · 2025-12-09
- Director, CEO AND CHAIR · Class B Common Stock → Class A Common StockDisposed 2 117 138conversion · 2025-12-09
- Director · Stock Option (right to buy) → Class A Common StockAcquired 61 000 @ $2,04grant · 2025-09-02
- Director · Stock Option (right to buy) → Class A Common StockAcquired 25 416 @ $2,18grant · 2025-07-07
- Director · Stock Option (right to buy) → Class A Common StockAcquired 30 500 @ $2,18grant · 2025-07-07
- Director · Stock Option (right to buy) → Class A Common StockAcquired 30 500 @ $2,18grant · 2025-07-07
- Director · Stock Option (right to buy) → Class A Common StockAcquired 30 500 @ $2,18grant · 2025-07-07
- Director · Stock Option (right to buy) → Class A Common StockAcquired 30 500 @ $2,18grant · 2025-07-07
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Seer Inc Market data — financials · 2026-05-29
- Seer Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- PRESIDENT & CFO · Class A Common StockSold 7 303 @ $1,69$12K · 2026-05-20
- Chief Commercial Officer · Class A Common StockOther 75 000 · 2026-05-08
- PRESIDENT & CFO · Class A Common StockSold 7 743 @ $1,99$15K · 2026-02-18
- Director, CEO AND CHAIR · Class A Common StockSold 24 385 @ $1,99$49K · 2026-02-18
- PRESIDENT & CFO · Class A Common StockOther 79 000 · 2026-02-03
- Director, CEO AND CHAIR · Class A Common StockOther 697 162 · 2026-02-03
- Director · Class A Common StockOther 4 088 · 2025-12-09
- Director, CEO AND CHAIR · Class A Common StockOther 1 438 057 · 2025-12-09
- Director, CEO AND CHAIR · Class A Common StockOther 2 117 138 · 2025-12-09
- PRESIDENT & CFO · Class A Common StockSold 6 797 @ $1,97$13K · 2025-11-19
- Director, CEO AND CHAIR · Class A Common StockSold 33 838 @ $1,97$67K · 2025-11-19
- Director · Class A Common StockOther 41 000 · 2025-09-02
- PRESIDENT & CFO · Class A Common StockSold 6 827 @ $2,04$14K · 2025-08-20
- Director, CEO AND CHAIR · Class A Common StockSold 33 992 @ $2,04$69K · 2025-08-20
- Director · Class A Common StockOther 17 083 · 2025-07-07
- Director · Class A Common StockOther 20 500 · 2025-07-07
- Director · Class A Common StockOther 20 500 · 2025-07-07
- Director · Class A Common StockOther 20 500 · 2025-07-07
- Director · Class A Common StockOther 20 500 · 2025-07-07
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -20.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 17.0%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -13.3%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 22.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.14xDerived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 3.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 15.0%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 20.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 12.84xDerived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 14.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 16.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -24.9%Derived (calculated)
- Return on equity (FY 2025-12-31): -28.4%Derived (calculated)
- Gross margin (FY 2025-12-31): 51.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -5.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -49.9%Derived (calculated)
- Net margin (FY 2025-12-31): -444.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -19.2%Derived (calculated)
- Total assets (annual): USD 296.08MSEC XBRL filing
- Total liabilities (annual): USD 36.78MSEC XBRL filing
- Current assets (annual): USD 201.53MSEC XBRL filing
- Cost of revenue (annual): USD 8.11MSEC XBRL filing
- Net income (annual): USD -73.6MSEC XBRL filing
- Shareholders' equity (annual): USD 259.31MSEC XBRL filing